Clinical Trials on Multiple Endocrine Neoplasia Type II

Total 59421 results

National Cancer Institute (NCI)

Completed

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

Multiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Medullary Thyroid Carcinoma

United States
Centre Hospitalier Universitaire Dijon

Unknown

Type 1 Multiple Endocrine Neoplasia Cohort Study (MEN1-GTEcohort)

Type 1-Multiple Endocrine Neoplasia Syndrome

France
Centre Hospitalier Universitaire Dijon

Recruiting

Study and Follow-up of Multiple Endocrine Neoplasia Type 1 (GENEM)

Multiple Endocrine Neoplasia

France
National University Health System, Singapore

Completed

Routine Transcervical Thymectomy in MEN-1 Patients

Thymic Carcinoid | Multiple Endocrine Neoplasia Type 1 (MEN-1)

Singapore
Centre Hospitalier Universitaire Dijon

Recruiting

Study and Monitoring of Multiple Endocrine Neoplasia Type 1 (NEM)

MEN1

France
National Cancer Institute (NCI)

Completed

Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients

Multiple Endocrine Neoplasia Type 2 | Medullary Thyroid Carcinoma

United States
University Hospital, Basel, Switzerland

Recruiting

Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial (LUMEN1)

MEN1 Gene Mutation

Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Neuroendocrine Neoplasm | Multiple Endocrine Neoplasia Type 1 | Advanced Carcinoid Tumor | Digestive System Neuroendocrine Neoplasm | Unresectable Carcinoid Tumor

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Multiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Recurrent Thyroid Gland Medullary Carcinoma | Hereditary Thyroid Gland Medullary Carcinoma | Locally Advanced Thyroid Gland Medullary Carcinoma | Sporadic Thyroid Gland Medullary Carcinoma | Stage III Thyroid Gland Medullary... and other conditions

United States
National Institute of Diabetes and Digestive and...

Recruiting

Natural History Study of Parathyroid Disorders

Primary Hyperparathyroidism | Pseudohypoparathyroidism | Parathyroid Cancer | Inheritable Bone Diseases | Multiple Endocrine Neoplasia, Type 1

United States
M.D. Anderson Cancer Center

Active, not recruiting

Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2

Multiple Endocrine Neoplasia Syndromes

United States
J.M. de Laat
Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaborators

Recruiting

Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients (PRIME)

Multiple Endocrine Neoplasia Type 1 | Neuroendocrine Tumor of Pancreas

Netherlands
Guangxi Medical University

Recruiting

EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumor | Multiple Endocrine Neoplasia Type 1

China
National Cancer Institute (NCI)

Completed

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

Pancreatic Neuroendocrine Carcinoma | Multiple Endocrine Neoplasia Type 1

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Meningioma | Neuroendocrine Neoplasm | Multiple Endocrine Neoplasia Type 1 | Von Hippel-Lindau Syndrome | Metastatic Well Differentiated Neuroendocrine Neoplasm | Somatostatin Positive Neoplastic Cells Present

United States
National Taiwan University Hospital

Recruiting

A Retrospective Study for Multiple Endocrine Neoplasia

Multiple Endocrine Neoplasia

Taiwan
M.D. Anderson Cancer Center

Active, not recruiting

Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)

Genetic Mutation | MEN1

United States
M.D. Anderson Cancer Center

Completed

Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes

Multiple Endocrine Neoplasia

United States
Jersey Shore University Medical Center
Rutgers University; Rutgers Cancer Institute of New Jersey

Completed

Genetic Evaluation of Families With Endocrine Cancers (MEN1)

Pancreatic Cancer | Parathyroid Disease | Thymic Cancer | MEN1 Syndrome

United States
The Cleveland Clinic

Withdrawn

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Plasma Cell Neoplasm

United States
National Institute of Diabetes and Digestive and...

Completed

Studies of Inherited Diseases of Metabolism

Multiple Endocrine Neoplasia

United States
Oncotherapeutics

Withdrawn

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Plasma Cell Neoplasm

United States
Genzyme, a Sanofi Company

Completed

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

Thyroid Cancer

Italy, Spain, Romania, Netherlands, Canada, United States, Switzerland, Australia
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic

Completed

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Multiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
City of Hope Medical Center

Completed

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Institute of Diabetes and Digestive and...

Completed

Studies of Elevated Parathyroid Activity

Hyperparathyroidism | Multiple Endocrine Neoplasia | Hypercalcemia | MEN1 | Parathyroid Neoplasm

United States
Microbio Co Ltd

Completed

Postbiotic MBS and Metformin Combination in Patients With T2DM

Type-II Diabetes

Taiwan
KeyBioscience AG
Eli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...

Terminated

A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM

Type II Diabetes Mellitus

Germany
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (CARAMEL 2)

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
HealthInsight
Center for Technology and Aging; Voxiva

Unknown

Mobile Health Technology as an Intervention for Diabetes Self-Management (Care4Life)

Type II Diabetes Mellitus

United States
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States, Canada
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
University of Southern California
National Cancer Institute (NCI); Celgene Corporation

Terminated

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
Mayo Clinic

Completed

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

Multiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Multiple Myeloma in Relapse

United States

Clinical Trials on Multiple Endocrine Neoplasia Type II

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations